TP53-mutated AML patient responders to flotetuzumab therapy had significantly higher tumor inflammation signature, FOXP3, CD8, inflammatory chemokine, and PD1 gene expression scores at baseline compared with non-responders [90]. The gene discussed is FOXP3; the disease is acute myeloid leukemia.